Lupus & antiphospholipid syndrome
Predictors of flare in SLE patients fulfilling lupus low disease activity state: a cohort study of 292 patients with 36-month follow-up
Authors' conclusion
In patients with LLDAS, anti-U1RNP, disease activity scored by SLE-DAS and SLE requiring maintenance immunosuppressants predict higher risk of flare. Remission with no glucocorticoids is associated with lower risk of flares.
Study context
- Population
- SLE patients attaining lupus low disease activity state (LLDAS), followed in a referral centre over 3 years
- Participants
- 292 patients
- Outcome
- Predictors of flare (r-SFI, SLEDAI-2K and SLE-DAS definitions)
- Follow-up
- Up to 36 months
Methodological detailssingle referral centre, multivariate Cox regression, 36-month follow-up
- Single referral centre
- Multivariate Cox regression
- 36-month follow-up
Main finding
As reported in the abstract
Predictors of SLE-DAS flare (multivariate Cox regression)
Hazard ratio (95% CI)
anti-U1RNPpresence of anti-U1RNP
2.16(1.30–3.59)
SLE-DAS score at baseline
1.27(1.04–1.54)
Immunosuppressants
2.43(1.43–4.09)
Observational data: associations, not effects.
Further findings
SLE Disease Activity Score (SLE-DAS) flares in remitted patients with no GC
| HR (95% CI) | ||
|---|---|---|
| Remitted patients with no glucocorticoids | 0.60 (0.37–0.98) | |
| 0.20.5125Hazard ratio (log scale) |
Patients with ≥1 flare over follow-up, by flare instrument · up to 36 months
- r-SFI
- 28.4%
- SLE-DAS
- 24.7%
- SLEDAI-2K
- 13.4%
Original publication
Predictors of flare in SLE patients fulfilling lupus low disease activity state: a cohort study of 292 patients with 36-month follow-up. Rheumatology (Oxford). Published 27 February 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →